Objectives： The molecular targeting drugs for the treatment of B-cell lymphoma have been dramatically developed. Recently, novel drugs of monoclonal antibodies and small molecules are approved by US FDA （Food and Dr...Objectives： The molecular targeting drugs for the treatment of B-cell lymphoma have been dramatically developed. Recently, novel drugs of monoclonal antibodies and small molecules are approved by US FDA （Food and Drug Administration）. Key Findings： This review summarizes characteristics, mechanisms, and results of the trials in the novel molecular targeting drugs for B-cell lymphoma such as obinutuzumab, polatuzumab vedotin, ibrutinib, idelalisib, and venetoclax. Summary： As a novel anti-CD20 antibody, obinutuzumab has been clinically developed on going. ADC （antibody drug conjugate） against CD79b molecules is also developed for B-cell lymphoma. BCR pathway is one of the most crucial pathways, and ibrutinib is a BTK （Bruton＇s tyrosine kinase） inhibitor that is under development for the treatment of B-cell malignancies, including CLL （chronic lymphocytic leukemia）, MCL （mantle cell lymphoma）, and DLBCL （diffuse large B-cell lymphoma）, as well as FL （follicular lymphoma）. BCL-2 family dysfunction and impairment of apoptosis are common in most B-cell lymphoid malignancies. Venetoclax, which is a highly selective BCL-2 inhibitor, a mimic for its BCL2 homolog 3-domain to induce apoptosis, is also reported to be active against B-cell malignancies. Conclusions： Mechanism-based combination regimens including these drugs may be required in the future.展开更多
文摘Objectives： The molecular targeting drugs for the treatment of B-cell lymphoma have been dramatically developed. Recently, novel drugs of monoclonal antibodies and small molecules are approved by US FDA （Food and Drug Administration）. Key Findings： This review summarizes characteristics, mechanisms, and results of the trials in the novel molecular targeting drugs for B-cell lymphoma such as obinutuzumab, polatuzumab vedotin, ibrutinib, idelalisib, and venetoclax. Summary： As a novel anti-CD20 antibody, obinutuzumab has been clinically developed on going. ADC （antibody drug conjugate） against CD79b molecules is also developed for B-cell lymphoma. BCR pathway is one of the most crucial pathways, and ibrutinib is a BTK （Bruton＇s tyrosine kinase） inhibitor that is under development for the treatment of B-cell malignancies, including CLL （chronic lymphocytic leukemia）, MCL （mantle cell lymphoma）, and DLBCL （diffuse large B-cell lymphoma）, as well as FL （follicular lymphoma）. BCL-2 family dysfunction and impairment of apoptosis are common in most B-cell lymphoid malignancies. Venetoclax, which is a highly selective BCL-2 inhibitor, a mimic for its BCL2 homolog 3-domain to induce apoptosis, is also reported to be active against B-cell malignancies. Conclusions： Mechanism-based combination regimens including these drugs may be required in the future.
